We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up) (AMP Up)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02119702
Recruitment Status : Recruiting
First Posted : April 22, 2014
Last Update Posted : August 30, 2022
Sponsor:
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute on Drug Abuse (NIDA)
National Institute of Allergy and Infectious Diseases (NIAID)
NIH Office of AIDS Research (OAR)
National Institute of Mental Health (NIMH)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Deafness and Other Communication Disorders (NIDCD)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Dental and Craniofacial Research (NIDCR)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Tulane University School of Medicine
Information provided by (Responsible Party):
Paige Williams, Harvard School of Public Health (HSPH)

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a prospective cohort study designed to define the impact of HIV infection and antiretroviral therapy (ART) on young adults with perinatal HIV infection (YAPHIV) as they transition into adulthood. A group of uninfected young adults from a similar sociodemographic background and age distribution will be enrolled for comparison.

Condition or disease
HIV/AIDS

Detailed Description:

AMP Up aims to define the impact of HIV infection and antiretroviral therapy (ART) on young adults with perinatal HIV infection as they transition into adulthood. A group of uninfected young adults from a similar sociodemographic background and age distribution will be enrolled for comparison.

The primary objectives of this study are:

  • To identify infectious and non-infectious complications of HIV disease and toxicities resulting from long-term ART, including disease progression, immune dysfunction, viral resistance, end-organ disease, and mortality.

  • To define the impact of HIV infection and ART on the long-term clinical outcomes of young adults, including:

    • Metabolic abnormalities and risk factors for cardiovascular disease, including glucose and lipid metabolism, blood pressure, and body composition.
    • Sexually transmitted infections (Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, syphilis, human papillomavirus, genital warts and HSV) among males and females, and cervical HPV-associated pre-cancers and cancers and Mycoplasma genitalium and other vaginal microbiota among females.
    • Reproductive health, fertility, and pregnancy outcomes including mother-to-child transmission of HIV.

  • To define the impact of perinatal HIV infection, its concominant risk factors and ART on long-term neurocognitive and behavioral health outcomes, including:

    • Mental health and neurocognitive functioning.
    • Health care behaviors, including adherence to ART, participation in health care services, and transition to adult clinical care.
    • Risk behaviors, including sexual behavior and substance use.
    • Independent living skills, and vocational and education achievement necessary for successful transition to adult functioning and quality of life.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 850 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up)
Actual Study Start Date : April 2014
Estimated Primary Completion Date : July 2025
Estimated Study Completion Date : July 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
Infected Cohort
Perinatally HIV-infected participants at or beyond their 18th birthday at enrollment.
Uninfected Cohort
HIV-uninfected participant at or beyond their 18th birthday at enrollment. May have horizontally-acquired HIV infection.


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. HIV disease progression [ Time Frame: Annually for 6 years ]
    Factors of interest for this outcome include virologic suppression, immune impairment, immune activation, changes in ART, cumulative exposure to specific ART, viral resistance, co-infections, and host genetic polymorphisms. Data will be collected through chart abstraction and laboratory assessments.

  2. Metabolic abnormalities [ Time Frame: Annually for 6 years ]
    Factors of interest include BMI, body composition, systolic and diastolic blood pressure, lipid levels (total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides). Data will be collected by chart review, physical assessments, and laboratory evaluations.

  3. Sexually transmitted infections [ Time Frame: Annually for 6 years ]
    STI testing and chart review conducted annually.

  4. Pregnancies [ Time Frame: Annually for 6 years ]
    Data collected annually through online surveys and chart abstraction.

  5. Mental health problems [ Time Frame: Annually for 6 years ]
    Assessed at annually through the Patient Health Questionnaire (PHQ-9)) and General Anxiety Disorder-7 (GAD-7)

  6. ART adherence [ Time Frame: Annually for 6 years ]
    Data collected annually through an online survey.

  7. Prevalence of risk behaviors including risky sexual behavior and licit and illicit substance use [ Time Frame: Annually for 6 years ]
    Participants will complete an annual online survey.

  8. Transition to adult functioning [ Time Frame: Every 3 years for 6 years ]
    Every year participants will complete an online survey to collect data on educational attainment, employment, independent living and quality of life.

  9. Hearing dysfunction [ Time Frame: Every 3 years for 6 years ]
    Assessed through the NIH Toolbox and a questionnaire to be completed at Entry, Year 3 and Year 6 visits.

  10. Language development [ Time Frame: Once, at the Entry or Year 3 visit ]
    The Clinical Evaluation of Language Fundamentals (CELF) IV assessment will be completed at the Entry or Year 3 visit.

  11. End-organ disease [ Time Frame: Annually for 6 years ]
    Factors of interest for this outcome include virologic suppression, immune impairment, immune activation, changes in ART, cumulative exposure to specific ART, viral resistance, co-infections, and host genetic polymorphisms. Data will be collected through chart abstraction and laboratory assessments.

  12. Mortality [ Time Frame: Annually for 6 years ]
    Factors of interest for this outcome include virologic suppression, immune impairment, immune activation, changes in ART, cumulative exposure to specific ART, viral resistance, co-infections, and host genetic polymorphisms. Data will be collected through chart abstraction and laboratory assessments.

  13. Risk factors for cardiovascular disease [ Time Frame: Annually for 6 years ]
    Factors of interest include BMI, body composition, systolic and diastolic blood pressure, lipid levels (total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides) and cumulative cardiometabolic risk. Data will be collected by chart review, physical assessments, and laboratory evaluations.

  14. Cervical HPV-associated pre-cancers and cancers (among female participants) [ Time Frame: Annually for 6 years ]
    Data collected through annual chart review.

  15. Cognitive impairment [ Time Frame: Every 3 years for 6 years ]
    Assessed at Entry, Years 3, 6, 9, and 12 visits through the NIH Toolbox.

  16. Maternal-to-child HIV transmission [ Time Frame: Annually for 6 years ]
    Data collected through annual chart review.


Biospecimen Retention:   Samples With DNA
Plasma, serum, peripheral blood mononuclear cells (PBMCs), urine, throat wash/gargle, saliva, and vaginal swabs.

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
HIV-infected and -uninfected young adults 18 years of age or older at the time of enrollment born to HIV-infected mothers.
Criteria

Perinatally HIV-Infected Cohort

Inclusion Criteria:

  • Perinatal HIV infection as documented in the medical record
  • At or beyond their 18th birthday at the time of informed consent with no upper age limit

  • Willing to provide access to existing medical records

    • Available medical record documentation since early childhood of:

      • ART exposure history
      • Opportunistic infection prophylaxis exposure history
      • Viral load and CD4+ cell count history
      • Major medical events history
  • Willingness to participate and provide legal written consent

Exclusion Criteria:

  • HIV acquired by other than maternal-child transmission (e.g., blood products, sexual contact, and IV drug use) as documented in the medical record

Uninfected Cohort

Inclusion Criteria:

  • Absence of perinatal HIV infection as indicated in the medical record; the PHEU participant may have horizontally-acquired HIV infection
  • At or beyond their 18th birthday at the time of informed consent with no upper age limit
  • Willingness to participate and provide legal written consent

Exclusion Criteria:

  • Have confirmed perinatal HIV infection as documented in the medical record
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02119702


Contacts
Layout table for location contacts
Contact: Liz Salomon, EdM 617-432-6762 lsalomon@hsph.harvard.edu

Locations
Layout table for location information
United States, California
University of California San Diego Recruiting
La Jolla, California, United States, 92093
Principal Investigator: Stephen Spector, MD         
United States, Colorado
University of Colorado Denver Health Sciences Center Recruiting
Aurora, Colorado, United States, 80045
Principal Investigator: Elizabeth McFarland, MD         
United States, Florida
Children's Diagnostic and Treatment Center Recruiting
Fort Lauderdale, Florida, United States, 33316
Principal Investigator: Lisa Gaye Robinson, MD         
University of Miami Recruiting
Miami, Florida, United States, 33316
Principal Investigator: Gwendolyn Scott, MD         
United States, Illinois
Ann and Robert H. Lurie Children's Hospital Recruiting
Chicago, Illinois, United States, 60614
Principal Investigator: Ellen Chadwick, MD         
United States, Louisiana
Tulane University Health Sciences Center Recruiting
New Orleans, Louisiana, United States, 70112
Principal Investigator: Margarita Silio, MD         
Principal Investigator: Russel Van Dyke, MD         
United States, Massachusetts
Children's Hospital Boston Recruiting
Boston, Massachusetts, United States, 02115
Principal Investigator: Sandra Burchett, MD         
United States, New Jersey
Rutgers - New Jersey Medical School Recruiting
Newark, New Jersey, United States, 07101
Principal Investigator: Arry Dieudonne, MD         
United States, New York
Bronx Lebanon Hospital Center Recruiting
Bronx, New York, United States, 10457
Principal Investigator: Murli Purswani, MD         
Jacobi Medical Center Recruiting
Bronx, New York, United States, 10461
Principal Investigator: Andrew Wiznia, MD         
United States, Pennsylvania
St. Christopher's Hospital for Children Recruiting
Philadelphia, Pennsylvania, United States, 19134
Principal Investigator: Janet Chen, MD         
United States, Tennessee
St. Jude Children's Research Hospital Recruiting
Memphis, Tennessee, United States, 38105
Principal Investigator: Katherine Knapp, MD         
United States, Texas
Baylor College of Medicine Recruiting
Houston, Texas, United States, 77030
Principal Investigator: Mary Paul, MD         
Puerto Rico
San Juan Research Hospital Recruiting
San Juan, Puerto Rico, 00936
Principal Investigator: Nicolas Rosario, MD         
Sponsors and Collaborators
Harvard School of Public Health (HSPH)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute on Drug Abuse (NIDA)
National Institute of Allergy and Infectious Diseases (NIAID)
NIH Office of AIDS Research (OAR)
National Institute of Mental Health (NIMH)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Deafness and Other Communication Disorders (NIDCD)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Dental and Craniofacial Research (NIDCR)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Tulane University School of Medicine
Investigators
Layout table for investigator information
Principal Investigator: Paige L Williams Harvard School of Public Health (HSPH)
Principal Investigator: Russell Van Dyke, MD Tulane University School of Medicine
Principal Investigator: Katherine Tassiopoulos, DSc, MPH Harvard School of Public Health (HSPH)
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Publications of Results:

Other Publications:

Layout table for additonal information
Responsible Party: Paige Williams, Senior Lecturer on Biostatistics, Harvard School of Public Health (HSPH)
ClinicalTrials.gov Identifier: NCT02119702    
Other Study ID Numbers: HD052102 - PH300
PH300 ( Other Identifier: PHACS Protocol Number )
First Posted: April 22, 2014    Key Record Dates
Last Update Posted: August 30, 2022
Last Verified: August 2022
Keywords provided by Paige Williams, Harvard School of Public Health (HSPH):
HIV/AIDS, perinatal HIV infection
Additional relevant MeSH terms:
Layout table for MeSH terms
Acquired Immunodeficiency Syndrome
HIV Infections
Blood-Borne Infections
Communicable Diseases
Infections
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Lentivirus Infections
 Retroviridae Infections
RNA Virus Infections
Virus Diseases
Slow Virus Diseases
Genital Diseases
Urogenital Diseases
Immunologic Deficiency Syndromes
Immune System Diseases